Regeneron Pharmaceuticals, Inc. Net Income 2008–2025
Regeneron Pharmaceuticals, Inc. reported $4.50B of net income for fiscal 2025. That was 2.1% higher than fiscal 2024. Compared with fiscal 2020, the change was +28.2%.
| Fiscal year | Net Income | Net margin | Change (YoY) |
|---|---|---|---|
| FY 2025 | $4.50B | 31.4% | +2.1% |
| FY 2024 | $4.41B | 31.1% | +11.6% |
| FY 2023 | $3.95B | 30.1% | -8.9% |
| FY 2022 | $4.34B | 35.6% | -46.3% |
| FY 2021 | $8.08B | 50.2% | +129.9% |
| FY 2020 | $3.51B | 41.3% | +66.0% |
| FY 2019 | $2.12B | 32.3% | -13.4% |
| FY 2018 | $2.44B | 47.5% | +104.0% |
| FY 2017 | $1.20B | 20.4% | +33.8% |
| FY 2016 | $895.50M | 18.4% | +40.8% |
| FY 2015 | $636.06M | 15.5% | +88.1% |
| FY 2014 | $338.13M | 12.0% | -18.3% |
| FY 2013 | $413.74M | 19.7% | -44.9% |
| FY 2012 | $750.27M | 54.4% | +438.3% |
| FY 2011 | $-221.76M | -49.7% | -112.3% |
| FY 2010 | $-104.47M | -22.8% | -54.0% |
| FY 2009 | $-67.83M | -17.9% | +14.3% |
| FY 2008 | $-79.13M | -33.2% | — |
Source: Regeneron Pharmaceuticals, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open REGN 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Regeneron Pharmaceuticals, Inc. reported $4.50B of net income for fiscal 2025. That was 2.1% higher than fiscal 2024. Compared with fiscal 2020, the change was +28.2%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Regeneron Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeRegeneron Pharmaceuticals, Inc. — frequently asked questions
What is Regeneron Pharmaceuticals, Inc.'s net income?
Regeneron Pharmaceuticals, Inc. (REGN) reported net income of $4.50B for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Regeneron Pharmaceuticals, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.